新材料 新材料周报（260323-0327） 领先大市-B(维持) 2026 年 4 月 1 日 行业研究/行业周报 化学原料行业近一年市场表现 资料来源：常闻 相关报告： 实质中断，关注维生素、氨基酸产业机 遇-新材料周报（260302-0306）2026.3.12 【山证新材料】北美 CSP 资本支出强劲 增长，建议关注上游 AI 新材料发展机遇 -新材料周报（260202-0206） 2026.2.11 冀泳洁 博士 执业登记编码：S0760523120002 邮箱：jiyongjie@sxzq.com 申向阳 邮箱：shenxiangyang@sxzq.com 霍尔木兹海峡影响加剧，维生素"涨价潮"持续 摘要 二级市场表现 市场与板块表现：本周新材料板块上涨。新材料指数涨幅为 0.86%，跑赢创 业板指 2.54%。近五个交易日，合成生物指数下跌 0.92%，半导体材料下跌 2.80%， 电子化学品上涨 0.22%，可降解塑料下跌 2.05%，工业气体上涨 1.78%，电池化 学品上涨 10.69%。 产业链周度价格跟踪（括号为周环比变化） 氨基酸：缬氨酸(14550 元/吨，不变)、精氨酸(2325 ...

新材料 新材料周报（260323-0327） 领先大市-B(维持) 2026 年 4 月 1 日 行业研究/行业周报 化学原料行业近一年市场表现 资料来源：常闻 相关报告： 实质中断，关注维生素、氨基酸产业机 遇-新材料周报（260302-0306）2026.3.12 【山证新材料】北美 CSP 资本支出强劲 增长，建议关注上游 AI 新材料发展机遇 -新材料周报（260202-0206） 2026.2.11 冀泳洁 博士 执业登记编码：S0760523120002 邮箱：jiyongjie@sxzq.com 申向阳 邮箱：shenxiangyang@sxzq.com 霍尔木兹海峡影响加剧，维生素"涨价潮"持续 产业链周度价格跟踪（括号为周环比变化） 氨基酸：缬氨酸(14550 元/吨，不变)、精氨酸(23250 元/吨，不变)、色氨酸 (37000 元/吨，1.37%)、蛋氨酸(49000 元/吨，20.99%) 【山证新材料】霍尔木兹海峡商业航运 可降解材料：PLA(FY201 注塑级)(17800 元/吨，不变)、PLA(REVODE 201 吹膜级)(16800 元/吨，不变)、PBS(17000 元 ...

证券代码：600216 证券简称：浙江医药 公告编号：2026-008 浙江医药股份有限公司 与私募基金合作投资事项进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 4.备案编码：SBTE67 1.基金名称：厦门华犇启航股权投资合伙企业（有限合伙） 2.管理人名称：厦门华犇当代创业投资管理有限公司 3.托管人名称：招商银行股份有限公司 一、合作投资基本概述情况 2026 年 3 月 9 日，公司与普通合伙人厦门华犇当代创业投资管理有限公司、 有限合伙人蔡晓洋、俞逢佳、虞樟星签署《厦门华犇启航股权投资合伙企业（有 限合伙）之合伙协议》，共同投资厦门华犇启航股权投资合伙企业（有限合伙）， 合伙企业的全部认缴出资额为 3.20 亿元，公司作为有限合伙人以自有资金认缴 出资 1.57 亿元，占合伙企业认缴出资总额的 49.06%。根据公司《章程》等有关 规定，本次交易未达到公司董事会及股东会审议标准，无需提交董事会或股东会 审议。具体内容详见公司 2026 年 3 月 10 日披露于上海证券交易所官网 1 （w ...

Core Viewpoint - The recent surge in vitamin prices is primarily driven by proactive supply contraction rather than geopolitical conflicts, indicating that the vitamin industry has entered the early stage of a cyclical recovery [6][32]. Group 1: Price Surge Dynamics - Since the outbreak of the Middle East conflict in late February, the vitamin market has experienced a strong price increase, particularly for Vitamin A and E, due to supply pressures in Europe [2][3]. - Vitamin A prices rose from 60.5 yuan/kg to 110 yuan/kg, an increase of 82%, while Vitamin E prices increased from 57.5 yuan/kg to 97.5 yuan/kg, a rise of 70% [2]. - The core reason for the price increase is not the geopolitical situation but rather a deliberate reduction in supply by major producers [6][14]. Group 2: Supply Chain and Market Structure - The vitamin industry is characterized by a high concentration of production, with major players like DSM and BASF dominating the market, which gives them significant pricing power [11][14]. - The largest application of vitamins is in animal feed, accounting for 80% of usage, with a low cost impact on feed, making downstream demand relatively insensitive to price changes [9][10]. - Following a previous price war, major producers have shifted strategies from market share competition to proactive supply contraction to restore profitability [14][15]. Group 3: Future Supply and Market Outlook - The potential for a rapid recovery in supply over the next 1-2 quarters is low due to several factors, including the time required for European production facilities to restart and the lengthy process of building new capacity [19][22]. - The proactive supply control strategies employed by producers are likely to continue in the short term, as many products remain unprofitable [23]. - The current low inventory levels and tight supply conditions are a direct result of these strategies, suggesting that the price increase may persist in the near term [16][32]. Group 4: Investment Opportunities - Companies with strong pricing power and solid earnings visibility, such as New Hope Liuhe and Zhejiang Medicine, are positioned well in the current market environment [27]. - The focus should be on firms that can benefit from the price increases while maintaining low valuations, as well as those in sectors currently experiencing losses that may see price recovery [28].

Key Points - The article discusses significant events in the private equity fund market from March 9 to March 15, 2026, highlighting various funds established and their investment focuses [5]. Government-Backed Funds - The Beijing-Tianjin-Hebei Venture Capital Guidance Fund has completed its registration with a total scale of 50 billion yuan, focusing on early-stage investments in hard technology [7]. - The Chaoyang Science and Technology Innovation Fund is seeking GP for a sub-fund that will invest in the exhibition industry, emphasizing AI and big data applications [8]. - Guizhou Province has launched its first aviation industry guidance fund with an initial scale of 400 million yuan, targeting key enterprises in the aerospace sector [9]. - The Xuzhou Economic Development Zone has established a specialized industrial fund with a total scale of 1.5 billion yuan, focusing on smart manufacturing and digital economy [9]. - The Yancheng Economic and Technological Development Zone is selecting GP for a 1 billion yuan mother fund aimed at supporting advanced manufacturing [9]. Market-Driven Funds - The Huizhou Technology Innovation Fund has been established with a total scale of 500 million yuan, focusing on AI and life sciences [16]. - The Shanghai Pudong Intelligent Manufacturing Phase II Fund has been set up with an initial scale of 325 million yuan, targeting hard technology projects [17]. - Zijin Mining has established a 280 million yuan dual circulation fund focusing on logistics supply chain and new energy [17]. - Zhejiang Medicine has committed 157 million yuan to a private equity fund focusing on the biopharmaceutical sector [18]. - The Guangxi Wuzhou Zhongheng Group has announced a 150 million yuan investment in a venture capital fund targeting innovative biomedicine and medical devices [19]. Industry-Specific Funds - The Sichuan Oil and Gas Equity Investment Guidance Fund has been registered with a scale of 1 billion yuan, focusing on oil and gas exploration rights [14]. - The Wuxi Weiwang Innovative Drug Accelerator Fund has been signed with a total scale of 2 billion yuan, aimed at supporting innovative drug enterprises [11]. - The Yibin City has launched a 2 billion yuan AI industry development fund, focusing on AI applications and infrastructure [12]. - The Hangzhou Gongshu District Talent Intelligent Entrepreneurship Fund has been established with a scale of 80 million yuan, focusing on AI and life sciences [16]. - The Jiangsu Province has set up a 1.7 billion yuan fund targeting advanced manufacturing and core technologies [22].

Group 1 - China’s Ministry of Commerce reported that during recent negotiations, both China and the U.S. reached preliminary consensus on several issues, indicating a constructive dialogue [2] - The Financial Regulatory Bureau emphasized the need to effectively manage risks in key areas and support the resolution of debt risks for financing platforms, while preventing illegal financial activities [2] - The Ministry of Industry and Information Technology highlighted the importance of optimizing and upgrading the industrial system, promoting new technologies, and developing emerging industries such as integrated circuits and aerospace [3] Group 2 - Meta plans to invest up to $27 billion in AI company Nebius over the next five years, with Nebius set to provide dedicated computing power starting in 2027 [4] - The recent price fluctuations in major chemical products have not significantly impacted the profitability or gross margins of Sanlianban Sanfangxiang [6] - The methanol market has seen a slight price increase, but Chitianhua has not engaged in any export sales of its methanol products [7] Group 3 - Xiangyou Technology is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [9] - Huichuang Data plans to distribute a dividend of 3.4 yuan per share and expects a 68.32% year-on-year increase in net profit for 2025 [10] - Jinfang Energy anticipates a 176.06% year-on-year increase in net profit for 2025 and plans to distribute a dividend of 2.5 yuan per share [11]

证券代码：600216 证券简称：浙江医药 公告编号：2026-007 浙江医药股份有限公司 关于持股 5%以上股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持计划的主要内容 国投高科基于自身经营发展需要，计划于本公告披露之日起 15 个交易日后 的 3 个月内，通过集中竞价交易方式合计减持数量不超过 9,616,377 股，即不超 过公司总股本的 1%。在上述减持计划实施期间，公司发生派发红利、送红股、 转增股本、增发新股或配股等股本除权、除息事项，上述减持股份数量将相应进 行调整。 | 股东名称 | 国投高科技投资有限公司 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：无 | | | | 持股数量 | 150,127,573股 | | | | 持股比 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of price leadership in the pharmaceutical sector, particularly in the context of rising raw material costs due to geopolitical tensions and supply chain disruptions [2] - The report highlights the approval of China's first invasive brain-machine interface, marking a significant milestone in medical technology and potential market opportunities [5] - The report notes a strong trend in China's innovative drug exports, with a significant increase in licensing deals and collaborations, indicating robust growth in the sector [6] Summary by Sections Supply Chain and Pricing Dynamics - The report discusses the impact of macroeconomic changes on supply chains, particularly the price increases in upstream chemical products affecting pharmaceutical raw materials [2] - It mentions that 90% of monitored products saw price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] - Specific raw materials like Vitamin E and methionine have seen price increases of 40.54% and 84.66% respectively since the start of the year [2] Market Trends and Innovations - The report details the rising prices of disposable gloves due to increased costs of upstream materials, with notable price hikes in butadiene and acrylonitrile [3] - It highlights the competitive landscape for disposable gloves, noting that leading companies are leveraging their cost advantages to implement price increases [3] - The report also discusses the potential for domestic medical products to benefit from export controls on dual-use items, enhancing China's competitive edge [4] Regulatory Developments and Market Opportunities - The approval of the brain-machine interface by the National Medical Products Administration is a significant development, with a large potential patient base in China [5] - The report outlines the introduction of new pricing guidelines for invasive brain-machine interfaces, which could facilitate market entry and reimbursement [5] Investment Recommendations - The report recommends focusing on raw material producers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Yingke Medical and Blue Sail Medical in the disposable glove sector [8] - It suggests monitoring companies benefiting from resource management policies, such as Aidi Te, and those involved in the invasive brain-machine interface market, like Meihua Medical [8] - The report also emphasizes the growth potential in the small nucleic acid drug sector, recommending companies like Yuyuan Pharmaceutical and Sunshine Nuohe [8] Company Performance and Forecasts - The report provides earnings forecasts for key companies, indicating a positive outlook for several firms in the pharmaceutical sector, with specific EPS and PE ratios highlighted for investment consideration [9]

Investment Rating - The report maintains a "B" rating for the new materials sector, indicating a leading position in the market [2]. Core Insights - The new materials sector has experienced a decline, with the new materials index dropping by 5.28%, underperforming the ChiNext index by 2.83% [3][12]. - The ongoing geopolitical tensions in the Middle East, particularly the disruption of commercial shipping in the Strait of Hormuz, have created opportunities in the vitamin and amino acid industries due to supply shortages and rising prices [5]. - Key products such as Vitamin E and methionine have shown significant price increases, with Vitamin E reaching 66,500 CNY/ton (up 11.8% week-on-week) and methionine at 23,850 CNY/ton (up 24.54% week-on-week) [5]. Summary by Sections 1. Market Performance - The new materials sector has seen a downturn, with various sub-sectors such as semiconductor materials and electronic chemicals experiencing declines of 9.92% and 7.39% respectively over the past five trading days [3][16]. - The overall performance of the basic chemicals and new materials sectors has been negative, with the Shanghai Composite Index and ChiNext Index also showing declines [12]. 2. Price Tracking - Amino acids: Valine at 13,400 CNY/ton (-0.74%), arginine at 22,000 CNY/ton (unchanged), tryptophan at 33,000 CNY/ton (+0.46%), and methionine at 23,850 CNY/ton (+24.54%) [4]. - Vitamins: Vitamin A at 60,500 CNY/ton (unchanged), Vitamin E at 66,500 CNY/ton (+11.76%), and Vitamin D3 at 192,500 CNY/ton (unchanged) [4]. - Industrial gases: UPSSS grade hydrofluoric acid at 11,000 CNY/ton (unchanged) and EL grade hydrofluoric acid at 6,385 CNY/ton (unchanged) [4]. 3. Investment Recommendations - The report suggests focusing on companies within the vitamin and amino acid supply chains, particularly due to the current market dynamics influenced by geopolitical factors [5]. - Recommended companies include Xinhecheng, Andisu, Meihua Biological, and Zhejiang Medicine, which are expected to benefit from the rising prices of core products [5].